It will be changing from this week as things gear up for some interesting new perspectives on the Pharma CI front and I'd like to take the time to thank everyone for their patience during the hiatus.
Normal service will resume shortly.
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sPkqXv9tKyItvl5can-epT8VFohGfqfmEO1Ni4bZKQDia_6S-UuUkk5_muTpHbRZNj1jl2AjgJLic5mqoqrBxNOq5CBJe40pcuAx46iXQYurl-NwDWbRiHNC0aKRHPeaolPateeMomLOWtuqLkt-zb=s0-d)
Monday, August 24, 2009
Resumption after an extended hiatus
Things have been really insanely busy on the work front over the last year, necessitating some radical prioritisation and thus I have only posted on Pharma Strategy Blog instead of here and Oncology Market Trends.
It will be changing from this week as things gear up for some interesting new perspectives on the Pharma CI front and I'd like to take the time to thank everyone for their patience during the hiatus.
Normal service will resume shortly.
It will be changing from this week as things gear up for some interesting new perspectives on the Pharma CI front and I'd like to take the time to thank everyone for their patience during the hiatus.
Normal service will resume shortly.
Saturday, October 18, 2008
Increasing importance of competitive intelligence in bear markets
In tough economic times, many companies are forced to downsize, trim budgets and preserve profit margins, while expecting a leaner, meaner organisation to survive the tempest. The reality is that the changes leave fewer people to accomplish the same amount of work on less marketing dollars; productivity becomes the new name of the game.
This is where good companies get smarter and focus on cost effective ways of making their budgets go further. One of the biggest challenges with pure market research, for example, is that results are often regional, forcing clients to consider a broad selection of target markets in which to base future directions on. Cutting the scope (i.e. reducing the number of sites) risks missing key data and generalising on more limited patterns.
Enter competitive intelligence, a much broader, more strategic way of gathering general trend data that can help make sense of the market. It is also a good way of keeping tabs on your competitors, because the stronger ones will survive the downturns better.
There are a host of clever tools and secondary data sources out there that can be mined effectively and a big picture of the target market described without the need for repetitive and expensive traditional market research interviewing people or holding focus groups. This is a much more 'think outside of the box' approach that rewards creative, enterprising marketers who want to get ahead of their competition.
The lean and mean approach starting with competitive intelligence first means that you can now find the needles in the haystack to point you in the right direction first, then test the specifics rather than relentless and expensive iterations of field testing. After all, those market research honorariums soon start to add up when the budget is tight. As an analogy, if you think about an archer - how can you hit the target if you can't even see it?
What can companies gain from competitive intelligence prior to market research?
Essentially, because of it's highly strategic nature, competitive intelligence bridges the gap between management and customers. On the one hand clear, simple elucidation of the risks involved enable management to grasp the big picture quickly and easily, while also offering identifiable actions to the customer that can be executed. Suddenly, this simplification of the data to the salient points enables all levels of the organisation to unite and focus rather than get bogged down in masses of conflicting data.
Using this approach, well designed competitive intelligence and market research questions become complementary and provide a more robust solution of strategic oversight and deep dives into more targeted areas.
Sometimes less really is more.
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uhkVRboqNeOAODrL8E5YoJDkciZrAe3cQYL0NBu96lvUshZY5yDbv0uU2viLDWdimpfDYqYN8axqo8H4SDb0boXap9Fn2laW0Pe1hfKqTF6XAdzJU1FvzXyof6zMXHRePR5Fzq9JuyxEKyQniBO8ML=s0-d)
This is where good companies get smarter and focus on cost effective ways of making their budgets go further. One of the biggest challenges with pure market research, for example, is that results are often regional, forcing clients to consider a broad selection of target markets in which to base future directions on. Cutting the scope (i.e. reducing the number of sites) risks missing key data and generalising on more limited patterns.
Enter competitive intelligence, a much broader, more strategic way of gathering general trend data that can help make sense of the market. It is also a good way of keeping tabs on your competitors, because the stronger ones will survive the downturns better.
There are a host of clever tools and secondary data sources out there that can be mined effectively and a big picture of the target market described without the need for repetitive and expensive traditional market research interviewing people or holding focus groups. This is a much more 'think outside of the box' approach that rewards creative, enterprising marketers who want to get ahead of their competition.
The lean and mean approach starting with competitive intelligence first means that you can now find the needles in the haystack to point you in the right direction first, then test the specifics rather than relentless and expensive iterations of field testing. After all, those market research honorariums soon start to add up when the budget is tight. As an analogy, if you think about an archer - how can you hit the target if you can't even see it?
What can companies gain from competitive intelligence prior to market research?
Essentially, because of it's highly strategic nature, competitive intelligence bridges the gap between management and customers. On the one hand clear, simple elucidation of the risks involved enable management to grasp the big picture quickly and easily, while also offering identifiable actions to the customer that can be executed. Suddenly, this simplification of the data to the salient points enables all levels of the organisation to unite and focus rather than get bogged down in masses of conflicting data.
Using this approach, well designed competitive intelligence and market research questions become complementary and provide a more robust solution of strategic oversight and deep dives into more targeted areas.
Sometimes less really is more.
Friday, October 17, 2008
Using social media tools for competitive intelligence
The last few years have seen a rise in all sorts of web 2.0 social media tools, so much so that the choices are becoming rapidly bewildering. They range from old stalwarts such as LinkedIn, Facebook and Ning to new kids on the block such as Twitter and FriendFeed.
Image via CrunchBaseTwitter is a microblogging platform that allows you to follow and be followed by others, while communicating in short sentences of 140 characters or less. Currently, I'm following just over 900 people, a mix of life scientists, pharma and biotech people, tech geeks, cancer survivors, news feeds and friends.
This ecletic mix gives a rich diversity of information, sometimes it is seemingly impossible to keep up but by running the RSS feed of my stream into Google Reader, I can use it to find information with a few keywords more easily. Many of those I'm following share their blog feeds via shortened urls, which means that the tweet can be searched for important information on various cancer topics, for example.
Twitter also has an incorporated search function (formerly Summize), thus allowing the user to search the whole Twitterverse for useful nuggets of information. The other day, I needed some information on a pharma company and found some initial starting ideas for the project on Twitter search, which were later verified via other sources. Sometimes knowing where to look for the needles in the haystack is the hardest part.
Friendfeed is probably one of my favourite sites. This online web tool essentially acts as an aggregator for all the other feeds such as Twitter, Flickr, Identi.ca, blog RSS, Delicious, StumbleUpon, Digg etc, while at the same time allowing conversation to take place around the imported information. People also add news and opinions through the Friendfeed bookmarklet.
The real power of FriendFeed isn't just the conversation though (Twitter is a bit of an echo chamber in that respect), but in the rooms, where like minded folks can chat about topics of interest. One of my favourites is the Life Scientists room, which numbers quite a few bioinformaticians and other related topics. We all learn and share from each other, blog posts and bookmarks can be added and debated or questions posed to the collegiate group. All this rich information adds more than isolated comments on individual blogs alone.
Does it have practical uses? You betcha! A client recently needed some information on a diagnostic and I vaguely remembered I had seen a Delicious bookmark floating in my subconscious somewhere, but couldn't remember for the life of me who posted it. A few keystrokes later and I found it easily in Friendfeed; much faster than mindless Googling through pages and pages of irrelevant information!
All of these tools are a great way to keep up with the sheer pace of change and information that goes on in today's pharma and biotechnology world. While you won't remember or monitor every last pixel that passes you by, using aggregators such as FriendFeed and Google Reader do at least allow you to track and find things easily when you need them.
Priceless.
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_stjSOVUxGL4MCSUSQaK7-AOU5MErkqYIsTOaftPMTrGOyCWv2HX24LyQnGtAo1EmAatUGFgQ_rLP6cmtmjMwQZ_ohFeXTWRqbjXDthqzb9mEllN--m7WyQRFEUsLv7u0rrfCSYPkWejTTGPDRrK8w6=s0-d)
Image via CrunchBaseTwitter is a microblogging platform that allows you to follow and be followed by others, while communicating in short sentences of 140 characters or less. Currently, I'm following just over 900 people, a mix of life scientists, pharma and biotech people, tech geeks, cancer survivors, news feeds and friends. This ecletic mix gives a rich diversity of information, sometimes it is seemingly impossible to keep up but by running the RSS feed of my stream into Google Reader, I can use it to find information with a few keywords more easily. Many of those I'm following share their blog feeds via shortened urls, which means that the tweet can be searched for important information on various cancer topics, for example.
Twitter also has an incorporated search function (formerly Summize), thus allowing the user to search the whole Twitterverse for useful nuggets of information. The other day, I needed some information on a pharma company and found some initial starting ideas for the project on Twitter search, which were later verified via other sources. Sometimes knowing where to look for the needles in the haystack is the hardest part.
Friendfeed is probably one of my favourite sites. This online web tool essentially acts as an aggregator for all the other feeds such as Twitter, Flickr, Identi.ca, blog RSS, Delicious, StumbleUpon, Digg etc, while at the same time allowing conversation to take place around the imported information. People also add news and opinions through the Friendfeed bookmarklet.
The real power of FriendFeed isn't just the conversation though (Twitter is a bit of an echo chamber in that respect), but in the rooms, where like minded folks can chat about topics of interest. One of my favourites is the Life Scientists room, which numbers quite a few bioinformaticians and other related topics. We all learn and share from each other, blog posts and bookmarks can be added and debated or questions posed to the collegiate group. All this rich information adds more than isolated comments on individual blogs alone.
Does it have practical uses? You betcha! A client recently needed some information on a diagnostic and I vaguely remembered I had seen a Delicious bookmark floating in my subconscious somewhere, but couldn't remember for the life of me who posted it. A few keystrokes later and I found it easily in Friendfeed; much faster than mindless Googling through pages and pages of irrelevant information!
All of these tools are a great way to keep up with the sheer pace of change and information that goes on in today's pharma and biotechnology world. While you won't remember or monitor every last pixel that passes you by, using aggregators such as FriendFeed and Google Reader do at least allow you to track and find things easily when you need them.
Priceless.
Wednesday, October 1, 2008
Procrit linked to deaths in stroke patients
Johnson and Johnson's Ortho Biotech has informed the FDA of preliminary safety findings from a clinical trial conducted in Germany investigating the use of Procrit (epoetin alfa) to treat acute ischemic stroke. The clinical trial utilised doses of Procrit that were considerably higher than the doses recommended for the treatment of anemia as described in the FDA-approved labeling for the product.
The trial was designed to determine whether the drug could help patients who have had an acute ischaemic stroke, an unapproved indication in both the EU and US.
However, it seems that the results showed that over ninety days after the start of the trial, there were more deaths in the group of patients who received Procrit compared to patients who received the placebo (16% versus 9%). Approx. half of all deaths in both groups occurred within the first seven days after starting the drug, with death from intracranial hemorrhage (bleeding within the brain) occurring among approximately 4% of patients who received Procrit compared to 1% of patients in the placebo group.
Submission of additional data to the FDA is expected within the next few weeks. Once a review of these data is completed, it is likely that the FDA will communicate their conclusions and recommendations to the public. The finding of increased mortality in patients receiving Procrit in the German trial would suggest the need to closely monitor patients enrolled in other ongoing trials for adverse outcomes and to evaluate whether the potential benefits for enrolled patients outweigh the risks in these trials.
More information can be found on the FDA's Center for Drug Evaluation and Research (CDER) site.
Erythropoeitin stimulating agents (ESA's) have had a chequered history over the last year with a number of safety concerns arising to the authorities attention, including whether or not they stimulate tumour growth and increase the risk of death.
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_s7EpAY4yTTvkYwwxhCOztL6kaXvBYVM8k3XRbjS3kTTNg5v0_TIq86ylijA8YZYKEqZRZEZG3Bf2j1-D3-TEsh8KxgkUmbSaHwBpCxu1WFkdnx3x6PqbVlYIS7xA0dfiCJowOhHkNtC-bDcfCKJ7zp=s0-d)
The trial was designed to determine whether the drug could help patients who have had an acute ischaemic stroke, an unapproved indication in both the EU and US.
However, it seems that the results showed that over ninety days after the start of the trial, there were more deaths in the group of patients who received Procrit compared to patients who received the placebo (16% versus 9%). Approx. half of all deaths in both groups occurred within the first seven days after starting the drug, with death from intracranial hemorrhage (bleeding within the brain) occurring among approximately 4% of patients who received Procrit compared to 1% of patients in the placebo group.
Submission of additional data to the FDA is expected within the next few weeks. Once a review of these data is completed, it is likely that the FDA will communicate their conclusions and recommendations to the public. The finding of increased mortality in patients receiving Procrit in the German trial would suggest the need to closely monitor patients enrolled in other ongoing trials for adverse outcomes and to evaluate whether the potential benefits for enrolled patients outweigh the risks in these trials.
More information can be found on the FDA's Center for Drug Evaluation and Research (CDER) site.
Erythropoeitin stimulating agents (ESA's) have had a chequered history over the last year with a number of safety concerns arising to the authorities attention, including whether or not they stimulate tumour growth and increase the risk of death.
Thursday, September 11, 2008
Tuesday, September 2, 2008
Abiraterone and prostate cancer
One drug that has been tearing up the newsfeed this year is abiraterone, a novel drug in phase II trials for prostate cancer.
In February, data was presented at ASCO's Genito-urinary satellite meeting that looked promising. Dr D.C. Danila and researchers from Memorial Sloan Kettering reported a small phase II trial in castration resistant metastatic prostate cancer after failure of docetaxel therapy.
They looked at abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity. It was a multicenter trial using abiraterone 1000mg orally daily and prednisone 5mg daily. Successful abiraterone activity was defined as a PSA decline >50% in >30% of patients. It was defined as not successful if the PSA decline occurred in <10%>50% PSA decline. Radiological assessment was possible in 26 men who had at least 3 cycles of treatment. No decreases in bone metastasis by bone scans were noted, but some had unchanged bone scans. The addition of prednisone reduced the frequency of adverse events. Circulating tumor cells (CTCs) was used as an additional means to asses response to treatment and did correlate with PSA changes.
A total of >5 CTCs prior to treatment that decreased to <3 (link) - including more details on the company developing the agent.
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uu9AyAYiiJFz00m3GIFQasoPpFOCMAQl8wiHkXU7S1yibP3z8LKTXthvYXS6X3gTmV8LNo4l6fIQdVxiQfnduwjbYoiLtvV8BhKLLn9E7GzqKnhHjGZODLi9adqXVet5Vq5WkZLcgJstMG-H91WSe_=s0-d)
In February, data was presented at ASCO's Genito-urinary satellite meeting that looked promising. Dr D.C. Danila and researchers from Memorial Sloan Kettering reported a small phase II trial in castration resistant metastatic prostate cancer after failure of docetaxel therapy.
They looked at abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity. It was a multicenter trial using abiraterone 1000mg orally daily and prednisone 5mg daily. Successful abiraterone activity was defined as a PSA decline >50% in >30% of patients. It was defined as not successful if the PSA decline occurred in <10%>50% PSA decline. Radiological assessment was possible in 26 men who had at least 3 cycles of treatment. No decreases in bone metastasis by bone scans were noted, but some had unchanged bone scans. The addition of prednisone reduced the frequency of adverse events. Circulating tumor cells (CTCs) was used as an additional means to asses response to treatment and did correlate with PSA changes.
A total of >5 CTCs prior to treatment that decreased to <3 (link) - including more details on the company developing the agent.
Wednesday, August 20, 2008
New iPhone apps and Protein Drug Database
Image via Wikipedia One of coolest apps I've come across in the iTunes store is Molecules.It allows you to select different drugs or molecules from the database and see them in 3 dimensions on the screen. You can even zoom in and see close up detail.
For example, the crystal structure of the C-Abl kinase domain in complex with STI-571 (Gleevec) for Philadelphia-positive Chronic Myeloid Leukemia (CML) is a beautiful sight.
You can also see more details behind the structure, such as the reference, authors, number of atoms, PDB code, sequence etc.
A very useful tool on the iPhone.
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_ttj6hBtmHN8UvUthIrOcGFn_nkAy6uRjYicFUxDePMp4uU6Bp543Hw6wsPHr0zwJ0a7XLuy2OWesyLGOvHRhhdDOaTKVs3Vj4MF7LHeCjHrshU8pJUWBwEO52VaZzKOk6EtRBapcbhNWI-MG3dnnCr=s0-d)
Monday, July 28, 2008
Improving survival in Liver Cancer - at what cost?
No effective therapy is available for advanced hepatocellular carcinoma (liver cancer), it's a terminal condition. Over 18,000 people typically die from it in the USA each year. It is much more common in Africa and East Asia where the risk of infection from Hepatitis B and C is much higher, which are associated with increased risk factors for the disease.
Image via Wikipedia
In this month's New England Journal of Medicine, a randomised trial involving 602 patients with advanced hepatocellular carcinoma was reported. Sorafenib, a multikinase inhibitor of Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor, improved median survival by 3 months compared to placebo (10.7 vs. 7.9 months, P<0.001). Adverse events, including diarrhea and weight loss, were more frequent in patients receiving sorafenib.
Three months doesn't sound a lot, but improvements in cancer survival nearly always occur in small increments. The other side of the coin is at what cost?
An editorial by Dr Lewis Roberts in the same journal noted the following:
“The pharmacy price of sorafenib is approximately $5,400 per month in the United States, {euro}3,562 per month in France, $1,400 per month in Korea, and $7,300 per month in China. Even in industrial nations, the high cost of new drugs produces significant stresses on health system budgets. There are substantial ethical implications in having effective therapies available for life threatening diseases that are priced beyond the reach of the populations most in need of therapy.”
Would you pay $15,000 for an extra three months of life?
![Reblog this post [with Zemanta]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sYhr204TaAOfiUxJjRqdvDCpSvbhFaTxlFXFlVohqCHTXbWg4UhnlE6iXnrtfY1Lwtn99GvhTAKivMtM8p-WFaBIRrliQG0d9TOHY-LUsi0XvI0BQrfCOx5FxnZrwzCQWvKnVadBvMgh9IoePMY34U=s0-d)
Image via WikipediaIn this month's New England Journal of Medicine, a randomised trial involving 602 patients with advanced hepatocellular carcinoma was reported. Sorafenib, a multikinase inhibitor of Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor, improved median survival by 3 months compared to placebo (10.7 vs. 7.9 months, P<0.001). Adverse events, including diarrhea and weight loss, were more frequent in patients receiving sorafenib.
Three months doesn't sound a lot, but improvements in cancer survival nearly always occur in small increments. The other side of the coin is at what cost?
An editorial by Dr Lewis Roberts in the same journal noted the following:
“The pharmacy price of sorafenib is approximately $5,400 per month in the United States, {euro}3,562 per month in France, $1,400 per month in Korea, and $7,300 per month in China. Even in industrial nations, the high cost of new drugs produces significant stresses on health system budgets. There are substantial ethical implications in having effective therapies available for life threatening diseases that are priced beyond the reach of the populations most in need of therapy.”
Would you pay $15,000 for an extra three months of life?
Wednesday, July 23, 2008
15 minutes of fame in oncology
Wow, my blog on abiraterone in advanced prostate cancer got picked up last night by TopUSAsites for prostate cancer.
It looks like the drug is going to be a hot topic for a while, but caution against the hype is advised until we see whether reduction in PSA and tumour shrinkage actually translates to what really matters to patients - improved survival and better quality of life.
What say you?
It looks like the drug is going to be a hot topic for a while, but caution against the hype is advised until we see whether reduction in PSA and tumour shrinkage actually translates to what really matters to patients - improved survival and better quality of life.
What say you?
Sunday, July 20, 2008
A cancer patient's inspiring story
A lady who was diagnosed with non-Hodgkin's lymphoma (NHL) and relapsed on chemotherapy, tells her story about how she overcame the odds with a promising new approach called radioimmunotherapy:
VIDEO
There is always hope around the corner with new treatments coming on the market.
VIDEO
There is always hope around the corner with new treatments coming on the market.
Subscribe to:
Posts (Atom)
